More job cuts: where will it all end?
This article was originally published in Scrip
Executive Summary
When GlaxoSmithKline announced yesterday that it was pulling out of research into selected neuroscience areas like depression and pain, it signalled a new round of job cuts at the company. Last year, GSK reduced its headcount by around 6,000 people.